Immune Pharmaceuticals Competitors

Immune Pharmaceuticals (OTCMKTS:IMNPQ) and Peak Pharmaceuticals (OTCMKTS:PKPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Earnings & Valuation

This table compares Immune Pharmaceuticals and Peak Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Immune Pharmaceuticals and Peak Pharmaceuticals, as reported by MarketBeat.com.

Profitability

This table compares Immune Pharmaceuticals and Peak Pharmaceuticals' net margins, return on equity and return on assets.

Risk & Volatility

Immune Pharmaceuticals has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Peak Pharmaceuticals has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.

Summary

Immune Pharmaceuticals beats Peak Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Immune Pharmaceuticals (OTCMKTS:IMNPQ) and Tower One Wireless (OTCMKTS:TOWTF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Earnings & Valuation

This table compares Immune Pharmaceuticals and Tower One Wireless' revenue, earnings per share (EPS) and valuation.

Immune Pharmaceuticals has higher earnings, but lower revenue than Tower One Wireless.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Immune Pharmaceuticals and Tower One Wireless, as reported by MarketBeat.com.

Profitability

This table compares Immune Pharmaceuticals and Tower One Wireless' net margins, return on equity and return on assets.

Risk & Volatility

Immune Pharmaceuticals has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Tower One Wireless has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500.

Summary

Immune Pharmaceuticals beats Tower One Wireless on 2 of the 3 factors compared between the two stocks.

Acerus Pharmaceuticals (OTCMKTS:TRLPF) and Immune Pharmaceuticals (OTCMKTS:IMNPQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

0.0% of Acerus Pharmaceuticals shares are owned by institutional investors. 3.9% of Immune Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for Acerus Pharmaceuticals and Immune Pharmaceuticals, as provided by MarketBeat.com.

Profitability

This table compares Acerus Pharmaceuticals and Immune Pharmaceuticals' net margins, return on equity and return on assets.

Volatility and Risk

Acerus Pharmaceuticals has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500. Comparatively, Immune Pharmaceuticals has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.

Earnings and Valuation

This table compares Acerus Pharmaceuticals and Immune Pharmaceuticals' revenue, earnings per share and valuation.

Immune Pharmaceuticals has lower revenue, but higher earnings than Acerus Pharmaceuticals.

Summary

Immune Pharmaceuticals beats Acerus Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Nexien BioPharma (OTCMKTS:NXEN) and Immune Pharmaceuticals (OTCMKTS:IMNPQ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Nexien BioPharma and Immune Pharmaceuticals' top-line revenue, earnings per share and valuation.

Profitability

This table compares Nexien BioPharma and Immune Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for Nexien BioPharma and Immune Pharmaceuticals, as provided by MarketBeat.

Risk and Volatility

Nexien BioPharma has a beta of -701.47, suggesting that its share price is 70,247% less volatile than the S&P 500. Comparatively, Immune Pharmaceuticals has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.

Summary

Immune Pharmaceuticals beats Nexien BioPharma on 3 of the 3 factors compared between the two stocks.

Immune Pharmaceuticals (OTCMKTS:IMNPQ) and Williston (OTCMKTS:WHCA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Immune Pharmaceuticals and Williston, as provided by MarketBeat.

Earnings and Valuation

This table compares Immune Pharmaceuticals and Williston's top-line revenue, earnings per share (EPS) and valuation.

Risk & Volatility

Immune Pharmaceuticals has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Williston has a beta of -1.09, suggesting that its stock price is 209% less volatile than the S&P 500.

Profitability

This table compares Immune Pharmaceuticals and Williston's net margins, return on equity and return on assets.

Summary

Immune Pharmaceuticals beats Williston on 1 of the 1 factors compared between the two stocks.

Immune Pharmaceuticals (OTCMKTS:IMNPQ) and Acura Pharmaceuticals (OTCMKTS:ACUR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Immune Pharmaceuticals and Acura Pharmaceuticals, as provided by MarketBeat.

Earnings and Valuation

This table compares Immune Pharmaceuticals and Acura Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Risk & Volatility

Immune Pharmaceuticals has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Acura Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

Profitability

This table compares Immune Pharmaceuticals and Acura Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Immune Pharmaceuticals beats Acura Pharmaceuticals on 3 of the 5 factors compared between the two stocks.